It is the mission of the FOXG1 Research Foundation to accelerate research to find successful therapeutics for FOXG1 syndrome and related neurological disorders.

The FRF mission includes:

- Funding cutting-edge science by the world's leading researchers that is integral along the Path to a Cure.

- Finding precise treatments and ultimately a cure for all patients with FOXG1 syndrome in the world for all ages, all mutation types, all geographies

- Providing equal access to therapeutics for all patients with FOXG1 syndrome in the world

- Uncovering the links between FOXG1 and related CNS disorders

- Advocating for FOXG1 patients worldwide

- Supporting FOXG1 families worldwide

- Continuously identifying gaps that slow rare CNS drug development, and developing solutions.

- Pioneering new methods to accelerate the road to rare CNS drug development

Since 2017 The FOXG1 Research Foundation has:

- Built the global rare disease patient organization

- Raised $5M

- Funded 11 academic labs

- Achieved biotech investment

- Uncovered critical scientific data

- Developed and characterized key FOXG1 assets spanning all varients

- Moved from basic science to translational experiments

- Launched multiple FRF chapters internationally, including Australia and Spain

- Pioneered a new model for conducting Natural History Studies to improve the quality and depth of data and accelerate the road to clinical drug development

- Became Chan Zuckerberg Initiative Rare As One strategic partners

- Became leaders in the rare disease patient organization space

*Spelling Key: FOXG1 - the gene in humans | Foxg1- the gene in mouse models | FOXG1 and Foxg1 in italics- refers to the proteins, not the gene itself, respectively in humans and models.